Novo Nordisk's Positive Results Send Encouraging Signal to Investors

Dow Jones11-04 21:32

1332 GMT - Novo Nordisk's financial results are highly positive overall, with an underlying performance that is clearly better than expected and an upward revision to guidance that exceeds expectations, Sydbank's senior analyst Soren Lontoft Hansen writes. "Novo delivered positive growth rates in the third quarter, sending a very encouraging signal to investors regarding the trade-off between lower prices and increased volume." Sydbank notes the better-than-expected performance of Novo's GLP-1 business, covering both obesity and diabetes treatments. Wegovy pill sales of 5.4 billion Danish kroner came in 17% above expectations, driven by the U.S. and a "very encouraging" initial launch outside the U.S., according to the analyst. This partially offsets a modest decline for the injectable version of Wegovy, reflecting a drop in the U.S. due to increased competition and price pressure. Shares are up 5.3%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment